ER
Unclaimed author profile

Erfan Amini

· Tehran University of Medical Sciences

Is this your research profile?

Create or sign in to your KnowledgeTrend account to claim this page. After the claim, this same profile URL and its linked publications will belong to your account. Claiming does not automatically grant a verified badge.

Create account and claim this profile Sign in to claim
2Linked publications
0Citations
0h-index
0i10-index

Metrics are calculated from publications currently linked to this profile.

Researcher overview

About

Erfan Amini is a registered researcher in their academic field.

Research output

Recent Publications

2 research works linked to this profile

▤
Global Cancer Incidence and Screening, COVID-19 and healthcare impacts, Hematological disorders and diagnostics · 2019 · JAMA Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

Christina Fitzmaurice, Degu Abate, Naghmeh Abbasi, Hedayat Abbastabar, Foad Abd-Allah, Omar Abdel‐Rahman, Ahmed Abdelalim, Amir Abdoli, Ibrahim Abdollahpour, Abdishakur S. M. Abdulle, Nebiyu Dereje Abebe, Haftom Niguse Abraha, Laith J. Abu‐Raddad, Ahmed Abualhasan, Isaac Akinkunmi Adedeji, Shailesh M Advani, Mohsen Afarideh, Mahdi Afshari, Mohammad Aghaali, Dominic Agius, Sutapa Agrawal, Ayat Ahmadi, Elham Ahmadian, Ehsan Ahmadpour, Muktar Beshir Ahmed, Mohammad Esmaeil Akbari, Tomi Akinyemiju, Ziyad Al‐Aly, Assim M. AlAbdulKader, Fares Alahdab, Shazia Alam, Genet Melak Alamene, Birhan Alemnew, Kefyalew Addis Alene, Cyrus Alinia, Vahid Alipour, Syed Mohamed Aljunid, Fatemeh Allah Bakeshei, Majid A. Almadi, Amir Almasi‐Hashiani, Ubai Alsharif, Shirina Alsowaidi, Nelson Alvis‐Guzmán, Erfan Amini, Saeed Amini, Yaw Ampem Amoako, Zohreh Anbari, Nahla Anber, Cătălina Liliana Andrei, Mina Anjomshoa, Fereshteh Ansari, Ansariadi Ansariadi, Seth Christopher Yaw Appiah, Morteza Arab‐Zozani, Jalal Arabloo, Zohreh Arefi, Olatunde Aremu, Habtamu Abera Areri, Al Artaman, Hamid Asayesh, Ephrem Tsegay Asfaw, Alebachew Fasil Ashagre, Reza Assadi, Bahar Ataeinia, Hagos Tasew Atalay, Zerihun Ataro, Suleman Atique, Marcel Ausloos, Leticia Ávila‐Burgos, Euripide Avokpaho, Ashish Awasthi, Nefsu Awoke, Beatriz Paulina Ayala Quintanilla, Martin Amogre Ayanore, Henok Tadesse Ayele, Ebrahim Babaee, Umar Bacha, Alaa Badawi, Mojtaba Bagherzadeh, Eleni Bagli, Senthilkumar Balakrishnan, Abbas Balouchi, Till Bärnighausen, Robert J. Battista, Masoud Behzadifar, Meysam Behzadifar, Bayu Begashaw Bekele, Yared Belete Belay, Yaschilal Muche Belayneh, Kathleen Berfield, Adugnaw Berhane, Eduardo Bernabé, Mircea Beuran, Nickhill Bhakta, Krittika Bhattacharyya, Belete Biadgo, Ali Bijani, Muhammad Shahdaat Bin Sayeed, Charles Birungi, Catherine Bisignano

Importance Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs). Conclusions and Relevance The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.

▤
Global Cancer Incidence and Screening, Multiple and Secondary Primary Cancers, Cancer Risks and Factors · 2018 · JAMA Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

Christina Fitzmaurice, Tomi Akinyemiju, Faris Lami, Shazia Alam, Reza Alizadeh‐Navaei, Christine A. Allen, Ubai Alsharif, Nelson Alvis‐Guzmán, Erfan Amini, Benjamin O. Anderson, Olatunde Aremu, Al Artaman, Solomon Weldegebreal Asgedom, Reza Assadi, Tesfay Mehari Atey, Leticia Ávila‐Burgos, Ashish Awasthi, Huda Omer Ba Saleem, Aleksandra Barać, James R. Bennett, Isabela M. Benseñor, Nickhill Bhakta, Hermann Brenner, Lucero Cahuana-Hurtado, Carlos A Castañeda-Orjuela, Ferrán Catalá-López, Jee-Young J Choi, Devasahayam Jesudas Christopher, Sheng‐Chia Chung, María Paula Curado, Lalit Dandona, Rakhi Dandona, José das Neves, Subhojit Dey, Samath Dhamminda Dharmaratne, David Teye Doku, Tim Driscoll, Manisha Dubey, Hedyeh Ebrahimi, Dumessa Edessa, Ziad El‐Khatib, Aman Yesuf Endries, Florian Fischer, Lisa M Force, Kyle J Foreman, Solomon Weldemariam Gebrehiwot, Sameer Vali Gopalani, Giuseppe Grosso, Rahul Gupta, Bishal Gyawali, Randah R Hamadeh, Samer Hamidi, James Harvey, Hamid Yimam Hassen, Roderick J. Hay, Simon I Hay, Behzad Heibati, Molla Kahssay Hiluf, Nobuyuki Horita, Hung Chak Ho, Olayinka Stephen Ilesanmi, Kaire Innos, Farhad Islami, Mihajlo Jakovljević, Sarah Charlotte Johnson, Jost B Jonas, Amir Kasaeian, Tesfaye Kassa, Yousef Khader, Ejaz Ahmad Khan, Gulfaraz Khan, Young‐Ho Khang, Mohammad Hossein Khosravi, Jagdish Khubchandani, Jacek A Kopec, G Anil Kumar, Michael Kutz, Deepesh Lad, Alessandra Lafranconi, Qing Lan, Yirga Legesse, James Leigh, Shai Linn, Raimundas Lunevičius, Azeem Majeed, Reza Malekzadeh, Déborah Carvalho Malta, LG Mantovani, Brian J. McMahon, Toni Meier, Yohannes Adama Melaku, Mulugeta Melku, Peter Memiah, Walter Mendoza, Tuomo J Meretoja, Haftay Berhane Mezgebe, Ted R. Miller, Shafiu Mohammed, Ali H. Mokdad, Mahmood Moosazadeh

Importance: The increasing burden due to cancer and other noncommunicable diseases poses a threat to human development, which has resulted in global political commitments reflected in the Sustainable Development Goals as well as the World Health Organization (WHO) Global Action Plan on Non-Communicable Diseases. To determine if these commitments have resulted in improved cancer control, quantitative assessments of the cancer burden are required. Objective: To assess the burden for 29 cancer groups over time to provide a framework for policy discussion, resource allocation, and research focus. Evidence Review: Cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) were evaluated for 195 countries and territories by age and sex using the Global Burden of Disease study estimation methods. Levels and trends were analyzed over time, as well as by the Sociodemographic Index (SDI). Changes in incident cases were categorized by changes due to epidemiological vs demographic transition. Findings: In 2016, there were 17.2 million cancer cases worldwide and 8.9 million deaths. Cancer cases increased by 28% between 2006 and 2016. The smallest increase was seen in high SDI countries. Globally, population aging contributed 17%; population growth, 12%; and changes in age-specific rates, -1% to this change. The most common incident cancer globally for men was prostate cancer (1.4 million cases). The leading cause of cancer deaths and DALYs was tracheal, bronchus, and lung cancer (1.2 million deaths and 25.4 million DALYs). For women, the most common incident cancer and the leading cause of cancer deaths and DALYs was breast cancer (1.7 million incident cases, 535 000 deaths, and 14.9 million DALYs). In 2016, cancer caused 213.2 million DALYs globally for both sexes combined. Between 2006 and 2016, the average annual age-standardized incidence rates for all cancers combined increased in 130 of 195 countries or territories, and the average annual age-standardized death rates decreased within that timeframe in 143 of 195 countries or territories. Conclusions and Relevance: Large disparities exist between countries in cancer incidence, deaths, and associated disability. Scaling up cancer prevention and ensuring universal access to cancer care are required for health equity and to fulfill the global commitments for noncommunicable disease and cancer control.